Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial

Transplantation and Cellular Therapy(2022)10.1016/j.jtct.2022.08.010Source: DataRank Database

The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial is a research paper published in Transplantation and Cellular Therapy (2022). On theSindex it has a DataRank of 0. It has been cited 32 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access32 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.79)OA: hybridTopics (29)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

John Kuruvilla ORCID,Julia Thornton Snider ORCID,Sachin Vadgama ORCID,Rob Blissett,Fadoua El Moustaid ORCID

Live enrichment

PubMed:35970302 OpenAlex:https://openalex.org/W4290851731

National Cancer Institute Division of Cancer Prevention

Grant: P30 CA008748

National Institutes of Health

Grant: 2P30CA008748-43

MOUSE GENETICS

FWCI

2.79

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.jtct.2022.08.010

publisherhttps://doi.org/10.1016/j.jtct.2022.08.010

publisherhttps://api.elsevier.com/content/article/PII:S2666636722015482?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666636722015482?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35970302

Fields of Study

CAR-T cell therapy research03 medical and health sciences0302 clinical medicine

MeSH Terms

Receptors, Chimeric AntigenBiological ProductsCost-Benefit AnalysisHumansNeoplasm Recurrence, LocalUnited StatesLymphoma, Large B-Cell, DiffuseAntigens, CD19

Keywords

MedicineChemoimmunotherapyCost effectivenessQuality-adjusted life yearClinical trialOncologyInternal medicineLymphomaRituximabBiological ProductsReceptors, Chimeric AntigenCost-Benefit AnalysisAntigens, CD19HumansLymphoma, Large B-Cell, DiffuseNeoplasm Recurrence, LocalArticleUnited States

Sustainable Development Goals

SDG 3: 3. Good health